Effect of Empagliflozin on Inflammation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07292909

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Hotel Dieu de France Hospital (from the registry)
Registry
  • NCT NCT07292909
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Lebanon (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07292909. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-01 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Empagliflozin on Inflammation
Acronym
EMPANTINFLAM
Condition
Inflamation
Intervention (Drug)
Empagliflozin (SGLT2i)
Intervention (Drug)
Placebo
Lead sponsor
Hotel Dieu de France Hospital (class: other)

Record details

Record id
cardio:ct-nct07292909
Content hash
5079d778e9a3ad77ea9c0b7db6bbc598c025e1267a92171ab6ec378c26246363